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Abstract
Background: Renal insufficiency (RI) is an independent risk factor for the adverse cardio-
vascular events. Long-term clinical outcome of percutaneous coronary intervention (PCI) in 
patients with RI is unknown especially in the era of first generation drug-eluting stents (DES). 
This study aims at comparing clinical outcomes between sirolimus-eluting stents (SES) and 
paclitaxel-eluting stents (PES) based on large scaled registry.
Methods: Patients who underwent PCI with DES from January 2004 to December 2009 in 
the Catholic University of Korea-PCI (COACT) registry were prospectively enrolled. A group of 
1,033 patients with RI, defined as estimated glomerular filtration rate under 60 mL/min, were 
analyzed. Major adverse cardiac events (MACE), including all-cause death, non-fatal myocar-
dial infarction (MI), target lesion revascularization (TLR), and target vessel revascularization 
(TVR) according to the type of stents were compared.
Results: Median follow-up period was 810 days (interquartile range: from 361 to 1,354 days). 
A group of 612 (59.2%) patients were treated with SES and 421 (40.8%) patients were treated 
with PES. The PES vs. SES group had significantly higher rate of MACE (35.9% vs. 28.3%, p =  
= 0.01). In multivariate Cox hazard regression analysis, PES vs. SES group had significantly 
higher rate of MACE (adjusted hazard ratio [AHR] 1.29, 95% confidence interval [CI] 1.02– 
–1.64, p = 0.033), particularly pronounced by all-cause death (AHR 1.34, 95% CI 1.008–1.770; 
p = 0.044). In further analysis with propensity score matching, overall findings were consistent.
Conclusions: In patients with RI, PCI using PES provides poorer clinical outcomes than 
SES in terms of MACE and all-cause death. (Cardiol J 2016; 23, 6: 637–646)
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Introduction
Renal insufficiency (RI) is an independent 
risk factor for development of cardiovascular dis-
ease and death [1]. According to the clinical data 
in patients with RI, mild to severe degree of RI 
substantially increases the risk of major adverse 
cardiovascular events (MACE) after percutaneous 
coronary intervention (PCI) [2, 3]. While perform-
ing PCI in these patients, using the drug eluting 
stent (DES) is superior to using bare metal stent 
(BMS) in terms of mortality [4, 5] or in-stent 
restenosis [6]. However, there was paucity of data 
on the long-term efficacy and safety in performing 
PCI with different kinds of DES. Comparisons of 
clinical and angiographic outcomes concerning first 
generation DES  performed in several randomized 
trials and meta-analyses [7] of 16 randomized tri-
als report that sirolimus-eluting stents (SES) are 
superior to paclitaxel-eluting stents (PES) in terms 
of target vessel revascularization (TVR) and stent 
thrombosis. However, a recently published retro-
spective study [8] on moderate to severe RI sug-
gests that the rates of MACE and all-cause death 
were similar in both stent groups. Controversy in 
these studies may result from different characteris-
tics of enrolled subjects, especially decreased renal 
function and duration of follow-up suggesting that 
further studies are required in RI setting. Based on 
our large scaled registry containing “real-world” 
data of all-comers, we aimed to compare the long-
-term clinical outcomes between SES and PES in 
patients with RI.
Methods
Study population and COACT registry
The COACT (CathOlic university of Korea 
— percutAneous Coronary inTervention) regis-
try is a large, prospective observational registry 
of demographic, clinical and procedural data, and 
short-term and long-term clinical outcome data of 
all patients undergoing PCI with the use of DES 
from 8 affiliated hospitals of The Catholic Univer-
sity of Korea between January 2004 and December 
2009 [9]. All the hospitals perform high-volume 
PCI (> 500 PCI/year) and are located throughout 
the country. There was no industry involvement 
in the design, conduct, or analysis of the study. 
The institutional review boards at each hospital 
approved the study.
For the present study, 1,033 out of total 9,293 
registered patients who had RI and underwent 
PCI with first generation DES (only SES or PES) 
were analyzed. Exclusion criteria were as follows: 
patients with normal renal function; patients un-
derwent PCI by other type of DES except SES or 
PES; patients underwent PCI by mixed SES and 
PES; patients with kidney transplantation (Fig. 1).
PCI procedure and medical treatment
All patients except for those who previously 
received aspirin or thienopyridines were adminis-
tered a loading dose of aspirin (300 mg), and clopi-
dogrel 600 mg before PCI. The standard protocol 
for renoprotective regimens was pre-hydration 
with intravenous 0.9% NaCl saline infusion at 
Figure 1. Study flow chart; COACT — CathOlic University of Korea: percutAneous Coronary inTervention; DES — drug 
eluting stents; GFR — estimated glomerular filtration rate; MDRD — Modification of Diet in Renal Disease; PCI — per-
cutaneous coronary intervention; PES — paclitaxel-eluting stent; SES — sirolimus-eluting stent.
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0.5–1 mL/kg/h according to the patients’ condition 
(left ventricular ejection fraction, renal replace-
ment therapy) the day before and after PCI proce-
dure. Nephrotoxic agents including non-steroidal 
anti-inflammatory drugs, metformin, and diuretics 
were avoided before the procedure. N-acetyl-
cysteine was not used routinely.
The procedure was performed through femoral 
or radial artery after administration of unfractionated 
heparin (100 U/kg). During the procedure, patients 
received unfractionated heparin to maintain an ac-
tivated clotting time between 250 s and 300 s. The 
choice of stent was at each physician’s discretion 
and the stent was deployed after balloon angioplasty. 
A successful PCI procedure was defined as decrease 
in minimum stenosis diameter to < 30% with throm-
bolysis in myocardial Infarction (TIMI) grade III flow 
on coronary angiogram. After discharge, patients 
continued receiving the same medications except 
for some intravenous or temporary medications.
Study definition and clinical follow-up
Renal insufficiency was defined as estimated glo-
merular filtration rate (GFR) < 60 mL/min/1.73 m2 
according to Modification of Diet in Renal Disease 
(MDRD) formula. The serum creatinine as a neces-
sary laboratory finding for GFR by MDRD formula 
was obtained before index PCI. Clinical and labora-
tory data were collected by independent research 
personnel using electronic medical records. During 
study periods, the initial DES implanted date was 
defined as index PCI date, and the following clinical 
outcome was reviewed by local events committee 
of the Cardiovascular Center of Seoul St. Mary’s 
Hospital, Seoul, Korea. For the complete data, cen-
sored data on survival were additionally obtained 
from telephone interviews and from the database of 
the National Health Insurance Corporation, Korea 
using a unique personal identification number.
The endpoints of the present study were the 
composite of MACE including all-cause death, non-
fatal myocardial infarction (MI), TVR including tar-
get lesion revascularization (TLR). MI was defined 
as ischemic symptom with new ST segment change 
in electrocardiogram and elevated cardiac markers 
at least twice the upper limit of normal value. TLR 
was defined as ischemia-driven PCI of the target 
lesion resulting from restenosis or reocclusion 
within the stent or in the adjacent 5 mm of the distal 
or proximal segments [10]. TVR was also defined 
as ischemia-driven PCI or bypass of any segment 
of the epicardial coronary artery containing the 
target lesion [10]. Stent thrombosis was defined 
as the occurrence of a thrombotic event classified 
as definite, probable, or possible, according to the 
Academic Research Consortium definition [10]. 
All clinical outcomes of interest were confined by 
source document and centrally adjudicated at the 
Cardiovascular Center of Seoul St. Mary’s Hospital, 
Seoul, Korea, by an independent group of clinicians 
who were unaware of patient’s status. Clinical, an-
giographic, procedural, operative, or outcome data 
were collected in the dedicated PCI and surgical 
databases by independent research personnel. For 
validation of complete follow-up data, informa-
tion on censored survival data was obtained to 
31 December, 2010 from the database of the National 
Health Insurance Corporation, Korea, with the use 
of a unique personal identification number.
Statistical analysis
Continuous variables were presented as mean 
± standard deviation and compared using in-
dependent t-test or Mann-Whitney U test. Cat-
egorical variables were presented as frequency 
with percentages (%) and compared by c2 test or 
Fisher’s exact test. Kaplan-Meier survival curves 
for cumulative survival were drawn and compared 
by log-rank test.
To reduce the impact of treatment selection 
bias and potential confounding in an observational 
study, we performed propensity score (PS) match-
ing. We estimated PS for the type of DES using 
a non-parsimonious multivariable logistic regres-
sion model. In this model, age above 65-year-old, 
gender, hypertension, diabetes, dyslipidemia, 
smoking, family history of coronary artery disease, 
previous history of MI, acute coronary syndrome 
(ACS), ejection fraction, dialysis, number of lesion, 
location of lesion, complex lesion, number of stent, 
total length of stent, stent diameter, and type of 
DES were included as covariates. The model was 
well-calibrated (Hosmer-Lemeshow test: p = 0.13) 
with reasonable discrimination (c statistic = 0.68) 
[11]. We then applied PS, the single composite 
variable, to match each SES implanted patient 
with PES implanted patient with a very similar 
PS, thus matching 351 pairs (57.4% of the 612 
were treated with SES and 83.4% of the 421 were 
treated with PES) with similar PS. In our match-
ing algorithm, we performed 1:1 match iteration 
by similar PS from initial 8 to 1 digit. After all of 
the PS matches were performed, we assessed the 
balance in baseline covariates between the two 
intervention groups with the paired t-test or the 
Wilcoxon signed rank test for continuous variables, 
and McNemar’s test or the marginal homogeneity 
test for categorical variables. Comparisons were 
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completed with Cox regression models with robust 
standard errors that accounted for clustering of the 
matched pairs.
All analyses were two-tailed, p-value < 0.05 
was considered to indicate the statistical signifi-
cance. Statistical analyses were performed by SAS 
software, version 9.1 (SAS Institute, Cary, North 
Carolina) and R programming language.
Results
Characteristics of study populations
Of all the 1,033 patients, 612 patients were 
implanted with SES for 752 lesions and 421 pa-
tients were implanted with PES for 530 lesions. 
The baseline demographic, clinical, laboratory, 
and angiographic characteristics between the two 
groups are shown in Tables 1–3. Baseline clinical 
characteristics were comparable, except proportion 
of current smoking, previous MI, previous PCI, 
and ACS, which factors were more in PES group. 
SES group had higher proportion of dyslipidemia. 
In angiographic findings, PES group had more right 
coronary artery lesion and complex lesion, how-
ever, the number of stents per patient was lower 
in PES group than SES group (1.3 ± 0.8 vs. 1.5 ± 
± 0.8, p = 0.001, respectively). The medication at 
discharge showed significant differences in statin, 
angiotensin converting enzyme inhibitors/angio-
tensin receptor blockers, b-blockers, and calcium 
channel blockers, which were more frequently 
prescribed in SES group (Table 4). In the propen-
sity matched population, there was no longer any 
significant difference for any covariate including 
dyslipidemia, history of current smoking, previous 
MI and previous PCI, clinical presentation, location 
of lesion, number of B2/C lesion, number of stent, 
and medication (Tables 1–4).
Follow-up and clinical outcomes
The median follow-up duration was 810 days 
(interquartile range [IQR] 361–1,354) for overall 
patient, 851 days (IQR 366–1356) in the SES group, 
and 772 days (IQR 357–1,363) in the PES group, 
which was not significantly different (p = 0.443). 
Complete follow-up data for major clinical events 
was obtained in 97.2% patients. During follow-up, 
173 (28.3%) patients had the composite of MACE 
in SES group and 151 (35.9%) patients in PES 
group (Table 5). A composite of MACE are higher 
in PES group compared with SES group (adjusted 
hazard ratio [HR] 1.29, 95% confidence interval 
[CI] 1.02–1.64; p = 0.03). All- cause death was 
significantly higher in PES group than SES group 
(adjusted HR 1.34, 95% CI 1.008–1.770; p = 
= 0.044). There was no significant difference in 
cardiac death, MI, repeat revascularization, and 
stent thrombosis between the groups. The inci-
dence of definite or probable stent thrombosis was 
10 (1.6%) in SES group and 8 (1.9%) in PES group. 
On the other hand, TVR including TLR was occurred 
more frequently in PES group than SES group before 
adjustment of baseline covariate, but there was no 
significant difference after rigorous adjustment of 
baseline covariates with multivariate Cox propor-
tional hazard regression model and PS matching. Sur-
vival analysis by Kaplan-Meier curve showed higher 
event rate for PES group in a composite of MACE, 
all-cause death, TLR, and TVR, respectively (Fig. 2). 
The trends of higher event rate for PES group in 
composite of MACE and all-cause death were consist-
ent, as shown in Table 5. Kaplan-Meier survival curve 
derived from propensity-matched population showed 
higher event rates in composite of MACE and it was 
pronounced by all-cause death (Fig. 3).
Subgroup analysis
We calculated the unadjusted HR for MACE 
in various subgroups (Fig. 4). The rate of MACE 
was numerically higher in the PES group than in 
the SES group in all subgroups, although statisti-
cal significance was not found in patients with 
age under 65, female gender, and non-ACS pres-
entation. There were no significant interactions 
between the stent type and MACE among the six 
subgroups. The subgroup analysis in propensity-
matched population had similar findings except that 
statistical significance was found in patients with 
age upper 65, male gender, ACS presentation, and 
non-dialysis.
Discussion
In the present study, compared to SES, PES 
implantation was an independent risk factor for the 
composite of MACE in patients with RI at long-
term clinical follow-up. This difference in primary 
object was originated from the higher event rates 
on all-cause death in PES group than SES group. 
To validate the predisposing baseline clinical 
characteristics and angiographic findings which 
were favorable for SES group, we used Cox hazard 
regression analysis and propensity score matching 
[12]. Statistical analysis also showed consistent 
gap in the composite of MACE and all-cause death 
between the SES and PES groups.
To date, this has been one of the largest pro-
spective observational study comparing SES with 
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Table 1. Baseline clinical characteristics and medication at discharge between the SES and PES groups.
Total population Propensity-matched population
SES  
(n = 612)
PES  
(n = 421)
P SES  
(n = 351)
PES  
(n = 351)
P
Age 68.2 ± 9.2 68.8 ± 10.7 0.33 68.4 ± 9.4 68.8 ± 10.8 0.87
Age ≥ 65 422 (69.0%) 294 (69.8%) 0.76 242 (69.0%) 244 (69.5%) 0.93
Male 284 (46.4%) 208 (49.4%) 0.34 169 (48.3%) 172 (49.0%) 0.88
Body mass index [kg/m2] 24.5 ± 3.3 24.3 ± 3.3 0.30 24.2 ± 3.1 24.3 ± 3.3 0.69
Hypertension 453 (74.0%) 310 (73.6%) 0.89 250 (71.2%) 250 (71.2%) 1.00
Diabetes 322 (52.6%) 238 (56.5%) 0.21 185 (52.7%) 192 (54.7%) 0.63
Dyslipidemia 154 (25.2%) 83 (19.7%) 0.04 70 (19.9%) 71 (20.2%) 1.00
Current smoker 111 (18.1%) 100 (23.8%) 0.03 85 (24.2%) 79 (22.5%) 0.59
Family history of CAD 25 (4.1%) 9 (2.1%) 0.09 11 (3.1%) 6 (1.7%) 0.27
Previous MI 30 (4.9%) 34 (8.1%) 0.04 23 (6.6%) 18 (5.1%) 0.52
Previous PCI 42 (6.9%) 51 (12.1%) < 0.01 37 (10.5%) 29 (8.3%) 0.29
Previous CABG 5 (0.8%) 7 (1.7%) 0.26 3 (0.9%) 6 (1.7%) 0.51
Clinical presentation: < 0.01 0.18
Stable angina 273 (44.6%) 133 (31.6%) 132 (37.6%) 117 (33.3%)
ACS 339 (55.4%) 288 (68.4%) 219 (62.4%) 234 (66.7%)
LVEF [%]* 56.7 ± 12.0 54.2 ± 12.3 < 0.01 55.9 ± 12.2 54.4 ± 11.9 0.09
LVEF < 45% 90 (14.7%) 87 (20.7%) 0.04 56 (16.0%) 65 (18.5%) 0.47
LVEF < 40% 56 (9.2%) 54 (12.8%) 0.16 35 (10.0%) 41 (11.7%) 0.68
LVEF < 35% 37 (6.1%) 31 (7.4%) 0.69 24 (6.8%) 23 (6.6%) 0.58
RI status: 0.13 0.20
Non-dialysis 562 (91.8%) 375 (89.1%) 328 (93.5%) 318 (90.6%)
Dialysis 50 (8.2%) 46 (10.9%) 23 (6.6%) 33 (9.4%)
Data are presented as mean ± standard deviation or n (%). *Left ventricular ejection fraction (LVEF) was available for 931 patients (90.1%); 
ACS — acute coronary syndrome; CABG — coronary artery bypass graft; CAD — coronary artery disease; MI — myocardial infarction;  
PCI — percutaneous coronary intervention; PES — paclitaxel-eluting stent; RI — renal insufficiency; SES — sirolimus-eluting stent
Table 2. Laboratory findings at index percutaneous coronary intervention and at follow-up according 
to follow-up HDL-C level.
Total population Propensity-matched population
SES 
(n = 612)
PES 
(n = 421)
P SES 
(n = 351)
PES 
(n = 351)
P
Glucose [mg/dL] 140.7 ± 83.0 150.0 ± 86.6 0.081 142.7 ± 87.1 147.4 ± 85.1 0.471
Hemoglobin [g/dL] 12.1 ± 2.0 12.0 ± 2.2 0.510 12.0 ± 2.0 12.0 ± 2.2 0.771
Creatinine [mg/dL] 1.97 ± 1.82 2.24 ± 2.30 0.043 2.03 ± 1.94 2.11 ± 2.14 0.600
MDRD [mL/min/1.73 m2] 43.9 ± 15.5 42.3 ± 17.0 0.325 43.6 ± 15.4 43.6 ± 16.4 0.991
MDRD < 30 107 (17.5%) 88 (20.9%) 0.172 59 (16.8%) 67 (19.1%) 0.491
Total cholesterol [mg/dL] 169.0 ± 54.6 158.0 ± 55.9 0.002 163.0 ± 54.8 158.0 ± 57.4 0.236
Triglyceride [mg/dL] 140.2 ± 107.0 117.8 ± 74.7 <0.001 131.7± 107.3 129.2 ± 74.2 0.776
LDL-C [mg/dL] 92.5 ± 54.0 86.2 ± 49.3 0.058 89.4 ± 52.6 86.4 ± 50.0 0.441
HDL-C [mg/dL] 37.8 ± 14.4 37.0 ± 14.7 0.364 37.5 ± 14.6 37.4 ± 14.9 0.893
Hs-CRP [mg/L] 1.65 ± 3.76 1.74 ± 3.87 0.716 1.83 ± 4.00 1.57 ± 3.70 0.366
Data are presented as mean ± standard deviation. HDL-C — high-density lipoprotein cholesterol; Hs-CRP — high-sensitivity C-reactive  
protein; LDL-C — low-density lipoprotein cholesterol; MDRD — Modification of Diet in Renal Disease; PES — paclitaxel-eluting stent;  
SES — sirolimus-eluting stent
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PES in patients with RI and these patients were 
excluded in large randomized controlled trial. In 
this regard, this study may provide invaluable 
long-term clinical outcome data for patients who 
underwent PCI using first generation DES with RI.
To the best of our knowledge, RI was signifi-
cantly associated with poor clinical outcomes in 
patients who underwent PCI regardless of the type 
of stent, BMS or DES [13–15]. Moreover, a few ret-
rospective studies have been published concerning 
clinical outcome of DES in RI. Lemos et al. [14] 
and Garg et al. [15] suggested that RI increased 
mortality after implantation of SES compared to 
the patients with normal kidney function, despite 
the clear antirestenotic effect of SES. The causes 
of these phenomena may be explained by several 
mechanisms. Firstly, vascular and atheroma calci-
fication is more severe and much more frequent 
in patients with RI than without RI [2, 16, 17]. 
Secondly, patients with RI was prone to the de-
velopment of endothelial dysfunction by excessive 
endothelin levels and diminished vascular nitric 
oxide production [18–20]. Besides, RI was associ-
ated with increased level of inflammatory factors, 
abnormal apolipoprotein levels, elevated plasma 
homocysteine, and enhanced coagulability [1]. 
For these reasons, MACEs occurred more fre-
quently (SES 28.3%, PES 35.9%, respectively) in 
the present study compared with previous studies 
on first generation DES [3, 7, 21].
In a few studies that showed the mortality 
benefit of DES compared with BMS in patients 
Table 3. Angiographic characteristics according to the type of stent.
Total population Propensity-matched population
SES 
(n = 612)
PES 
(n = 421)
P SES 
(n = 351)
PES 
(n = 351)
P
Number of lesion 1.2 ± 0.5 1.3 ± 0.5 0.342 1.3 ±0.6 1.2 ± 0.5 0.20
Location of lesion:
LMCA 43 (7.0%) 32 (7.6%) 0.73 21 (6.0%) 23 (6.6%) 0.88
LAD 486 (79.4%) 318 (75.5%) 0.14 263 (74.9%) 259 (73.8%) 0.79
LCx 296 (48.5%) 229 (54.4%) 0.06 172 (49.0%) 189 (53.9%) 0.22
RCA 307 (50.2%) 271 (64.4%) < 0.01 232 (66.1%) 213 (60.7%) 0.10
Number of B2/C lesion 0.9 ± 0.6 1.0 ± 0.7 0.01 0.9 ± 0.7 1.0 ± 0.7 0.26
Stent number per patient 1.5 ± 0.8 1.3 ± 0.8 < 0.01 1.4 ± 0.8 1.4 ± 0.7 0.25
Total stent length [mm] 36.3 ± 19.8 36.7 ± 22.3 0.78 35.9 ± 20.3 34.0 ± 20.8 0.16
Mean stent diameter [mm] 3.1 ± 0.3 3.1 ± 0.5 0.23 3.1 ± 0.3 3.1 ± 0.5 0.38
B2/C — complex lesion; LAD — left anterior descending artery; LCx — left circumflex artery; LMCA — left main coronary artery; PES —  
paclitaxel-eluting stent; RCA — right coronary artery; SES — sirolimus-eluting stent
Table 4. Medications according to the type of stent.
Total population Propensity-matched population
SES (n = 612) PES (n = 421) P SES (n = 351) PES (n = 351) P
Aspirin 580 (94.8%) 391 (92.9%) 0.21 330 (94.3%) 328 (93.5%) 0.88
Clopidogrel 540 (88.2%) 383 (91.0%) 0.15 325 (92.6%) 313 (89.2%) 0.17
Statin 457 (74.7%) 282 (67.0%) < 0.01 256 (72.9%) 236 (67.2%) 0.13
ACEI/ARB 413 (67.5%) 275 (65.3%) 0.02 237 (67.5%) 233 (66.4%) 0.13
Beta blocker 391 (63.9%) 268 (63.7%) 0.01 229 (65.2%) 219 (62.4%) 0.13
Calcium-channel blocker 175 (28.6%) 97 (23.0%) < 0.01 89 (25.4%) 79 (22.5%) 0.18
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin II receptor blocker; CCB — calcium channel blocker; PES — paclitaxel-
-eluting stent; SES — sirolimus-eluting stent
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Table 5. Clinical events in patients undergoing PCI by PES compared with SES.
SES PES Unadjusted HR 
(95% CI)
P Adjusted HR* 
(95% CI)
P
Total population (n = 1033) N = 612 N = 421
Composite of MACE 173 (28.3%) 151 (35.9%) 1.51 (1.21–1.88) < 0.01 1.29 (1.01–1.64%) 0.03
All-cause death 118 (19.3%) 111 (26.4%) 1.58 (1.22–2.05) < 0.01 1.34 (1.01–1.77) 0.04
Cardiac death 43 (7.0%) 40 (9.5%) 0.99 (0.64–1.52) 0.96 0.91 (0.57–1.44) 0.68
MI 7 (1.1) 7 (1.7%) 1.92 (0.67–5.49) 0.23 1.33 (0.42–4.23) 0.63
TLR/TVR 64 (10.5%) 52 (12.4%) 1.46 (1.01–2.11) 0.04 1.28 (0.86–1.91) 0.22
Propensity-matched  
population (n = 702)
N = 351 N = 351
Composite of MACE 108 (30.8%) 128 (36.5%) 1.48 (1.17–1.88) < 0.01 1.37 (1.06–1.78) 0.02
All-cause death 74 (21.1%) 94 (26.8%) 1.57 (1.18–2.09) < 0.01 1.43 (1.06–1.94) 0.02
Cardiac death 28 (8.0%) 32 (9.1%) 1.24 (0.75–2.06) 0.41 1.17(0.62–2.19) 0.63
MI 5 (1.4%) 6 (1.7%) 1.33 (0.46–3.89) 0.60 1.47 (0.45–4.82) 0.53
TLR/TVR 39 (11.1%) 44 (12.5%) 1.39 (0.94–2.04) 0.10 1.35 (0.88–2.09) 0.17
*Adjusted variables: age > 65, gender, family history of coronary artery disease, previous MI, previous PCI, previous coronary artery bypass 
grafting, diabetes, hypertension, hyperlipidemia, current smoking, acute coronary syndrome, ejection fraction < 35%, renal insufficiency state, 
location of lesion, number of lesion over B2C, number of stent, stent length, mean stent diameter; CI — confidence interval; HR — hazard ra-
tio; MACE — major adverse cardiovascular events; MI — myocardial infarction; PCI — percutaneous coronary intervention; PES — paclitaxel-
-eluting stent; SES — sirolimus-eluting stent; TLR/TVR — target lesion revascularization/target vessel revascularization
Figure 2. Kaplan-Meier curve for a composite of major adverse cardiac events (A), all-cause death (B), myocardial 
infarction (C), and target lesion revascularization/target vessel revascularization (D) between the SES and PES groups; 
PCI — percutaneous coronary intervention; PES — paclitaxel-eluting stent; SES — sirolimus-eluting stent.
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Figure 3. Kaplan-Meier Curve for a composite of major adverse cardiac events (A), all-cause death (B) myocar-
dial infarction (C), and target lesion revascularization/target vessel revascularization (D), between the propensity 
score matched SES and PES groups; PCI — percutaneous coronary intervention; PES — paclitaxel-eluting stent; 
SES — sirolimus-eluting stent.
with RI, the presumed causes of this result were 
related with selection bias and reduced restenosis 
in patients who underwent PCI by DES [4, 5]. 
Meta-analysis [7] of 16 randomized trials compar-
ing clinical outcome of SES and PES in general 
population has showed a better clinical outcome 
in SES than PES in the aspects of reintervention 
rate and stent thrombosis. Some random controlled 
trials report that SES has more beneficial impact 
on in-stent restenosis than PES [21–23]. Research-
ers suggested a few explanations based on the 
difference of pharmacological action, drug release 
kinetics, pattern of drug distribution in the arterial 
wall, and stent characteristics of SES and PES [24]. 
SES elutes nearly all of the loaded sirolimus in 
1 month from non-erodable polymer and PES 
releases paclitaxel as an initial burst followed by 
a constant slow release up to 3 months. In autopsy 
data, PES showed greater inflammation consisting 
of lymphocytes, eosinophils, and macrophages at 
4 months compared to SES [25].
In the present study, patients in PES group 
were more often current smokers, had previous MI, 
previous PCI, ACS, low ejection fraction, and num-
ber of B2/C lesions, and took less statins. In renal 
insufficiencies, calcified target lesion showed worse 
clinical outcome compared to non-calcified lesion 
in SES registry [26]. Even though we performed 
rigorous adjustments of these variables using mul-
tivariate Cox proportion hazards regression analysis 
and PS matching to minimize the bias of the registry 
data, we cannot rule out the possibility of overesti-
mation of mortality benefit of SES compared to PES.
Recently, it has been reported that there were 
no differences in MACE, mortality, or revasculari-
zation between SES and PES in patients with RI in 
2 papers [8, 27]. However, those papers contained 
smaller numbers of patients (141 in SES group, 287 
in PES group in 1 paper, 346 in SES group, 224 in 
PES group in the other) than the present study. In 
large scaled registry data [28] on ST elevation MI, 
SES and PES showed no differences in clinical out-
644 www.cardiologyjournal.org
Cardiology Journal 2016, Vol. 23, No. 6
come during median follow-up of 342 days. In those 
papers, there were no rigorous adjustments such 
as PS matching different to our study. As presented 
in our results of subgroup analysis, renal function 
of study population might affect the comparison of 
clinical outcome between the SES and PES group.
Limitations of the study
Our study has some limitations. First, the first 
generation DES are already getting old fashioned. 
Thus, the analysis of difference between the first 
generation stents might be no more needed, how-
ever, many patients have been already treated 
with these stents. Therefore, we need to know the 
clinical outcomes of the first generation stents in 
various clinical situations. Second, selection bias 
and confounding factors might have affected the 
results, because this study has a non-randomized 
observational design. To minimize these biases, we 
performed propensity-score matching, but hidden 
bias may still remain because of the influence of 
unmeasured confounders. Third, we did not col-
lect data on the development of contrast induced 
nephropathy, type of contrast, volume of contrast in 
this study. Because contrast-induced nephropathy 
is one of the important risk factors for worse clinical 
outcomes, we cannot exclude that this might affect 
the results. Fourth, detection of events and patient 
follow-up were less rigorous than in randomized 
controlled trials. Even though 97.2% of patients 
were followed and the data of the National Health 
Insurance Corporation were reviewed for survival, 
nonfatal events (e.g. MI or TVR) may have been 
underestimated. As the information on censored 
survival data was obtained from National Health 
Insurance Corporation as form of death or alive, 
classification of the cause of death was impossible 
in 94 patients (9.0% of total population). These 94 
patients were classified as non-cardiac death and 
early interruption of antiplatelet agent or tachyar-
rhythmia after revascularization may be related to 
cardiovascular cause of death but underestimated 
in this study. Fifth, coronary angiography was 
analyzed qualitatively, not quantitatively. Detailed 
quantitative coronary analysis may be helpful in 
further interpreting our findings.
Conclusions
In patients with RI, PCI using PES provides 
poorer long-term clinical outcome than SES in 
terms of MACE and all-cause death. There was no 
Figure 4. Comparative unadjusted hazard ratio (HR) of major adverse cardiac events (MACE) for subgroups; 
ACS — acute coronary syndrome; CI — confidence interval; GFR — glomerular filtration rate; PES — paclitaxel-eluting 
stents.
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difference of repeat revascularization between the 
SES and PES groups during 2.2 years of follow-up.
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